Health & bio

Boehringer Survodutide: 16.6% weight loss at 76 weeks

SYNCHRONIZE-1 Phase 3 GLP-1 plus glucagon dual agonist with waist-circumference reduction. Adverse events mild.

Primary sources · 1
Healthline Survodutide
← View the full 2026-04-10 (Friday) issue
What you're reading now arrives in your inbox daily at 21:00 UTC.

Get today's brief every day at 21:00 UTC

7 must-reads · 17 fields · tracked storylines delivered to your inbox daily. Pick only the fields you want; unsubscribe anytime.

Past issues →